CAPRICOR THERAPEUTICS INC

For the period ended Dec 31, 2023. Filed Mar 11, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 11, 2024

CAPR$8.87-9.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

FOR THE YEARS ENDED DECEMBER 31, 2023 AND 2022


· · Years ended December 31,
	2023	2022

REVENUE
Revenue	$25,178,066		$2,551,469

TOTAL REVENUE	25,178,066		2,551,469

OPERATING EXPENSES
Research and development	36,448,039		21,816,949
General and administrative	12,807,886		10,431,903

TOTAL OPERATING EXPENSES	49,255,925		32,248,852

LOSS FROM OPERATIONS	(24,077,859)		(29,697,383)

OTHER INCOME (EXPENSE)
Other income	67,657		190,582
Investment income	1,728,701		521,535
Loss on disposal of fixed assets	(6,041)		(34,266)

TOTAL OTHER INCOME (EXPENSE)	1,790,317		677,851

NET LOSS	(22,287,542)		(29,019,532)

OTHER COMPREHENSIVE INCOME (LOSS)
Net unrealized gain on marketable securities	130,569		105,244

COMPREHENSIVE LOSS	$(22,156,973)		$(28,914,288)

Net loss per share, basic and diluted	$(0.83)		$(1.18)
Weighted average number of shares, basic and diluted	26,778,360		24,552,688

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.